Aton Ra Partners Exact Sciences Corp Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Exact Sciences Corp stock. As of the latest transaction made, Aton Ra Partners holds 9,013 shares of EXAS stock, worth $485,980. This represents 1.33% of its overall portfolio holdings.

Number of Shares

9,013

Previous 9,859 8.58%

Holding current value

$485,980

Previous $672,000 0.89%

% of portfolio

1.33%

Previous 1.41%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$59.06 - $75.72 $49,964 - $64,059	-846 Reduced 8.58%	9,013 $666,000
Q3 2023 Oct 25, 2023	SELL	$65.94 - $99.04 $16,880 - $25,354	-256 Reduced 2.53%	9,859 $672,000
Q2 2023 Jul 18, 2023	SELL	$62.68 - $95.05 $88,692 - $134,495	-1,415 Reduced 12.27%	10,115 $949,000
Q1 2023 May 05, 2023	SELL	$47.19 - $70.77 $76,542 - $114,788	-1,622 Reduced 12.33%	11,530 $781,000
Q4 2022 Feb 02, 2023	BUY	$30.35 - $53.15 $22,398 - $39,224	738 Added 5.94%	13,152 $651,000
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $103,902 - $160,452	3,250 Added 35.46%	12,414 $403,000
Q2 2022 Aug 15, 2022	SELL	$35.61 - $76.23 $34,612 - $74,095	-972 Reduced 9.59%	9,164 $361,000
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $97,506 - $139,822	-1,694 Reduced 14.32%	10,136 $709,000
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $42,630 - $59,199	588 Added 5.23%	11,830 $921,000
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $132,923 - $182,725	1,473 Added 15.08%	11,242 $1.07 Million
Q2 2021 Aug 12, 2021	BUY	$93.66 - $139.27 $10,208 - $15,180	109 Added 1.13%	9,769 $1.21 Million
Q1 2021 May 17, 2021	BUY	$116.57 - $155.01 $1.13 Million - $1.5 Million	9,660 New	9,660 $1.27 Million

Others Institutions Holding EXAS

# of Institutions

671

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $9.54B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account